Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBT Margin (2021 - 2025)

Historic EBT Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 10.69%.

  • Tarsus Pharmaceuticals' EBT Margin rose 381300.0% to 10.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.13%, marking a year-over-year increase of 803100.0%. This contributed to the annual value of 63.16% for FY2024, which is 7157300.0% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' EBT Margin stood at 10.69%, which was up 381300.0% from 19.67% recorded in Q2 2025.
  • Tarsus Pharmaceuticals' EBT Margin's 5-year high stood at 33.11% during Q2 2021, with a 5-year trough of 4271.01% in Q4 2021.
  • For the 5-year period, Tarsus Pharmaceuticals' EBT Margin averaged around 765.63%, with its median value being 76.64% (2024).
  • Over the last 5 years, Tarsus Pharmaceuticals' EBT Margin had its largest YoY gain of 41347500bps in 2022, and its largest YoY loss of -37124100bps in 2022.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' EBT Margin stood at 4271.01% in 2021, then surged by 97bps to 136.26% in 2022, then tumbled by -138bps to 324.72% in 2023, then surged by 89bps to 34.76% in 2024, then skyrocketed by 69bps to 10.69% in 2025.
  • Its last three reported values are 10.69% in Q3 2025, 19.67% for Q2 2025, and 31.96% during Q1 2025.